This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miwa, S. Articles by Namiki, M. Search for Related Content PubMed PubMed Citation Articles by Miwa, S. Articles by Namiki, M.

The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4–Induced Invasion in Prostate Cancer

¹ Department of Urology, Kanazawa University, Kanazawa, Japan and ² Department of Urology, School of Medicine, and ³ Department of Periodontics, Prevention and Geriatrics, School of Dentistry, University of Michigan, Ann Arbor, Michigan

Requests for reprints: Atsushi Mizokami, Department of Urology, Kanazawa University, 13-14 Takaramachi, Kanazawa-city, Japan 920-8640. Phone: 81-76-265-2393; Fax: 81-76-222-6726; E-mail: mizokami{at}med.kanazawa-u.ac.jp.

Bisphosphonates are useful for the treatment of prostate cancer bone metastasis. However, the role of bisphosphonate on the development of the osteoblastic component of prostate cancer bone metastases is not defined. In the present study, the third-generation bisphosphonate, YM529 (minodoronate), was tested for its effects on the osteolytic PC-3 and novel osteoblastic LNCaP-SF cell lines. YM529 inhibited both osteolytic and osteoblastic changes in an intratibial tumor injection murine model. In vitro, YM529 inhibited both the proliferation and the invasion of both prostate cancer cell lines. The stromal cell–derived factor-1 (or CXCL12)/CXCR-4 pathway is believed to play an important role in the development of prostate cancer bone metastases. Thus, we determined if YM529 affected this pathway. YM529 suppressed CXCR-4 expression in PC-3 and LNCaP-SF in vitro and in vivo and this was associated with decreased in vitro invasion. These results suggest that YM529 may inhibit cancer cell invasion into the bone matrix by repressing the expression of CXCR-4 in bone metastasis lesions.

This article has been cited by other articles:

				T. TANAKA, H. KAWASHIMA, K. OHNISHI, K. MATSUMURA, R. YOSHIMURA, M. MATSUYAMA, K. KURATSUKURI, and T. NAKATANI Indirect Antitumor Effects of Bisphosphonates on Prostatic LNCaP Cells Co-cultured with Bone Cells Anticancer Res, April 1, 2009; 29(4): 1089 - 1094. [Abstract] [Full Text] [PDF]

				S. I. Seo, L. Gera, H. E. Zhau, W. P. Qian, S. Iqbal, N. A. Johnson, S. Zhang, M. Zayzafoon, J. Stewart, R. Wang, et al. BKM1740, an Acyl-Tyrosine Bisphosphonate Amide Derivative, Inhibits the Bone Metastatic Growth of Human Prostate Cancer Cells by Inducing Apoptosis Clin. Cancer Res., October 1, 2008; 14(19): 6198 - 6206. [Abstract] [Full Text] [PDF]

				O. Klezovitch, M. Risk, I. Coleman, J. M. Lucas, M. Null, L. D. True, P. S. Nelson, and V. Vasioukhin A causal role for ERG in neoplastic transformation of prostate epithelium PNAS, February 12, 2008; 105(6): 2105 - 2110. [Abstract] [Full Text] [PDF]

				Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption Cancer Res., April 15, 2007; 67(8): 3646 - 3653. [Abstract] [Full Text] [PDF]

				J. Liao, A. Schneider, N. S. Datta, and L. K. McCauley Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res., September 15, 2006; 66(18): 9065 - 9073. [Abstract] [Full Text] [PDF]